Myriad Genetics, a leader in genetic testing and precision medicine, has recently announced an exciting update to their MyRisk® with RiskScore® Breast Cancer Risk Assessment. This comprehensive risk model now includes breast density as a key factor, along with personal/family history and genetic markers. By incorporating this additional information, patients and healthcare providers can gain a m..
PaxMedica, a clinical stage biopharmaceutical company, has announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness study. The study successfully achieved its primary endpoint and demonstrated statistically significant and clinically meaningful results. These findings are an important step towards filing an NDA for the use of PAX-101 in the treatment of African Slee..
Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) and Incyte Corporation (Nasdaq: INCY) have announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial successfully met its primary endpoint, demonstrating an overall response rate (ORR) of 74% when administered at a dose of 0.3 mg/kg every two weeks. Furthermore, the data reve..
BioCardia Announces Pause in Enrollment for Phase III CardiAMP Cell Therapy Heart Failure Trial SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease treatment, has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to temporarily pause new..
Immatics N.V., a clinical-stage biopharmaceutical company, has announced that Bristol Myers Squibb (BMS) will be investing $35 million in the company. BMS acquired 2,419,818 ordinary shares of Immatics through a private placement transaction at a price of $14.461 per share. As part of the investment, BMS also gained the right to appoint a member to the Immatics Scientific Advisory Board. Harpree..
Grifols, a global leader in the production of plasma-derived medicines, has announced positive results from a Phase 4 study investigating the use of XEMBIFY®, its subcutaneous immunoglobulin product, administered every two weeks. The study successfully met its primary objective by demonstrating comparable levels of total immunoglobulins when compared to weekly administration in patients with pri..
Soaak Technologies, Inc., a renowned healthtech company known for their clinically proven sound frequency composition therapies, has recently been awarded a Phase I Small Business Innovation Research (SBIR) contract from the U.S. Air Force (USAF) for 2023. In collaboration with AFWERX and AFVentures, this contract aims to enhance the performance, capabilities, and mission readiness of Air Force ..
Rarecells, Inc. has made an exciting announcement about a major breakthrough in the detection of Circulating Giant Cancer Cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS).   In collaboration with Dr. Azra Raza from Columbia University Irving Medical Center, Rarecells has conducted groundbreaking research that has revealed the presence of CGCCs in MDS patients for the first time ..
